TABLE 3.
Potential predisposing factors and pathogenesis among 28 patients with Staphylococcus aureus pneumonia
| Predisposing factors and pathogenesis | n (%) |
|---|---|
| Health care-associated pneumonia (n=28) | 16 (57) |
| Long-term care facility resident (n=16) | 7 (44) |
| Acute care hospitalization within 30 days (n=16) | 4 (25) |
| Skin portal (n=16) | 8 (50) |
| Device-related (n=16) | 3 (19) |
| Pacemaker (n=16) | 2 (12) |
| Intravenous catheter (n=16) | 1 (6) |
| Immunosuppression* (n=16) | 5 (31) |
| Active neoplasm and chemotherapy (n=16) | 2 (12) |
| Transplant (n=16) | 1 (6) |
| Primary pneumonia and secondary bloodstream infection (n=16) | 8 (50) |
| Primary bloodstream infection and secondary pneumonia (n=16) | 8 (50) |
| Community-acquired pneumonia (n=28) | 12 (43) |
| Intravenous drug use (n=12) | 6 (50) |
| Skin portal (n=12) | 9 (75) |
| Primary pneumonia and secondary bloodstream infection (n=12) | 1 (8) |
| Primary bloodstream infection and secondary pneumonia (n=12) | 11 (92) |
*
Immunosuppression is defined as hypogammaglobulinemia, CD4 lymphocyte count less than 200×106/L, treatment with conventional immunosuppressives and corticosteroid use of oral prednisone ≥10 mg daily